Systematic Financial Management LP Grows Stock Holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Systematic Financial Management LP lifted its stake in Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 53.9% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 611,746 shares of the life sciences company's stock after buying an additional 214,272 shares during the quarter. Systematic Financial Management LP owned approximately 0.79% of Integra LifeSciences worth $11,115,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Sachem Head Capital Management LP purchased a new position in Integra LifeSciences during the third quarter worth approximately $44,153,000. Centiva Capital LP purchased a new position in Integra LifeSciences during the third quarter worth approximately $192,000. Clearline Capital LP boosted its position in Integra LifeSciences by 226.8% during the third quarter. Clearline Capital LP now owns 230,397 shares of the life sciences company's stock worth $4,186,000 after purchasing an additional 159,903 shares in the last quarter. Walleye Capital LLC boosted its position in Integra LifeSciences by 758.7% during the third quarter. Walleye Capital LLC now owns 234,506 shares of the life sciences company's stock worth $4,261,000 after purchasing an additional 207,196 shares in the last quarter. Finally, FORA Capital LLC purchased a new position in Integra LifeSciences during the third quarter worth approximately $436,000. Hedge funds and other institutional investors own 84.78% of the company's stock.

Insiders Place Their Bets

In other Integra LifeSciences news, EVP Michael J. Mcbreen sold 1,700 shares of the firm's stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $24.16, for a total transaction of $41,072.00. Following the completion of the sale, the executive vice president now owns 56,182 shares of the company's stock, valued at $1,357,357.12. This trade represents a 2.94 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 3.10% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on IART. Citigroup increased their price target on Integra LifeSciences from $16.00 to $22.00 and gave the stock a "sell" rating in a research report on Tuesday, November 5th. Truist Financial lowered their price target on Integra LifeSciences from $26.00 to $21.00 and set a "hold" rating on the stock in a research report on Monday, October 14th. Morgan Stanley began coverage on Integra LifeSciences in a report on Monday. They set an "underweight" rating and a $20.00 target price for the company. Bank of America reduced their target price on Integra LifeSciences from $26.00 to $18.00 and set an "underperform" rating for the company in a report on Monday, October 7th. Finally, BTIG Research raised Integra LifeSciences from a "sell" rating to a "neutral" rating in a report on Monday, October 7th. Three investment analysts have rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the company. According to MarketBeat, the company has an average rating of "Hold" and an average target price of $23.00.

Integra LifeSciences Price Performance

Shares of NASDAQ:IART traded up $0.24 during midday trading on Friday, hitting $24.10. The company had a trading volume of 415,162 shares, compared to its average volume of 1,078,542. Integra LifeSciences Holdings Co. has a twelve month low of $16.81 and a twelve month high of $45.42. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73. The stock has a market cap of $1.86 billion, a price-to-earnings ratio of -267.22, a price-to-earnings-growth ratio of 0.84 and a beta of 1.15. The business's 50-day simple moving average is $21.32 and its 200-day simple moving average is $23.92.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last posted its quarterly earnings results on Monday, November 4th. The life sciences company reported $0.41 EPS for the quarter, beating the consensus estimate of $0.39 by $0.02. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The firm had revenue of $380.80 million during the quarter, compared to analysts' expectations of $375.81 million. During the same quarter last year, the firm earned $0.76 earnings per share. The business's revenue for the quarter was down .4% on a year-over-year basis. On average, research analysts predict that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current year.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.